Skip to main content

Table 4 Dose interruption and resumption criteria for haematological toxicities related to myelosuppression [21]

From: Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Parameter

Interruption

Resumption criteriaa

Neutrophils

 < 0.5 × 109/L

 < 1.5 × 109/L

Platelets

 < 50 × 109/L

 > 75 × 109/L

  1. aResumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us